PA 1420

Drug Profile

PA 1420

Alternative Names: Polymyxin EI

Latest Information Update: 15 May 2001

Price : $50

At a glance

  • Originator Chiron Corporation
  • Class Antibacterials; Peptide antibiotics
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 15 May 2001 Discontinued-Clinical for Pseudomonal infections in USA (Inhalation)
  • 15 May 2001 Discontinued-Clinical for Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
  • 05 Oct 2000 PathoGenesis Corporation has been acquired by Chiron Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top